|本期目录/Table of Contents|

[1]马秀萍,张建中,景 丽,等.COX-2、P53、MDR-1/P-gp在乳腺癌中的表达 及其关系研究[J].宁夏医科大学学报,2011,(05):455-458.
 MA Xiu-ping,ZHANG Jian-zhong,JING Li,et al.The Expression of COX-2、P53 and MDR-1/P-gp in Breast Cancer[J].Ningxia Medical University,2011,(05):455-458.
点击复制

COX-2、P53、MDR-1/P-gp在乳腺癌中的表达 及其关系研究(PDF)
分享到:

《宁夏医科大学学报》[ISSN:1005-8486/CN:64-1029/R]

卷:
期数:
2011年05期
页码:
455-458
栏目:
论著
出版日期:
2012-12-30

文章信息/Info

Title:
The Expression of COX-2、P53 and MDR-1/P-gp in Breast Cancer
作者:
马秀萍12 张建中1 景 丽1 王 岩2 郭凤英1
1.宁夏医科大学基础医学院病理学教研室,银川 750001; 2.宁夏医科大学第二附属医院病理科,银川 750001
Author(s):
MA Xiu-ping12ZHANG Jian-zhong1JING Li1WANG-Yan2GUO Feng-ying1
1.Department of Pathology,Ningxia Medical University,Yinchuan 750004; 2.Department of Pathology,the Second Hospital of Ningxia Medical University,Yinchuan 750004
关键词:
环加氧化酶-2 P53 MDR-1/P-gp 多药耐药 乳腺癌
Keywords:
COX-2 P53 MDR-1/P-gp multi-drug resistance breast cancer
分类号:
R737.9
DOI:
-
文献标志码:
A
摘要:
目的 探讨乳腺癌组织中环加氧化物酶-2(COX-2)、抑癌基因P53及多药耐药基因MDR-1/P-gp的表达及其相互关系。方法 应用Envision免疫组织化学方法,半定量检测66例未经放、化疗的乳腺癌手术切除标本中COX-2、抑癌基因P53和MDR-1/P-gp的表达。结果 1.乳腺癌组织中COX-2、抑癌基因P53和MDR-1/P-gp的阳性表达率各为62.1%(41/66)、50%(33/66)和40.9%(27/66)。2.乳腺癌中COX-2的阳性表达与抑癌基因P53、多药耐药基因MDR-1/P-gp的阳性表达呈正相关(r分别为0.281和0.332,P<0.006)。3.抑癌基因P53的阳性表达与多药耐药基因MDR-1/P-gp的阳性表达呈正相关(r=0.277,P=0.024)。结论 在乳腺癌组织中联合检测COX-2、P53和MDR-1/P-gp可以更好的指导临床乳腺癌的预后,可作为评估乳腺癌进展和判断预后的重要指标,寻找治疗乳腺癌新的作用靶点,同时对这些指标及其相关性的研究为其抑制剂在临床的应用或联合应用提供一定的分子学依据。
Abstract:
Objective To detect the expression of COX-2、P53 and MDR-1/P-gp in breast cancer and their correlations. Methods Immunohistochemistry analyses was used to detect the expression of COX-2、P53 and MDR-1/P-gp in 66 cases of breast cancer without chemotherapy.Results 1.These positive rate of COX-2、P53 and MDR-1/P-gp protein in breast cancer tissue were 62.1%(41/66)、50%(33/66)and 40.9%(27/66)respectively.2.The over-expression of COX-2 protein was positively correlated with the expression of P53 and MDR-1/P-gp protein.(r=0.281 and 0.332, P<0.006). 3.The over-expression of P53 protein was positively correlated with the expression of MDR-1/P-gp protein(r=0.277,P=0.024). Conclusions Determination of the above genes expression in breast cancer tissue can be of use in deciding the degree of malignancy and prognosis of brest cancer. COX-2、P53 and MDR-1/P-gp expression may be closely related to diagnosis and prognosis of patients. They might be biomarkers and as therapeutic targets in breast cancer. Research on the above genes expression and their relationship can provide molecular basis for clinical practice.

参考文献/References:

[1] Valerie R, David K, Ennapadam V, et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer [J]. Cancer Res, 1995,55(21):5038-5042.
[2] Singh B,Berry JA, ShoherA, et al. COX-2 over-expression increases motility and invasion of breast cancer cells [J].Int Joncol, 2005, 26(5): 1393-1399.
[3] Ristimaki A,Sivula A,Lundin J, et al.Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer [J].Cancer Res, 2002, 62(3):632-635.
[4] Xu XC.COX-2 inhibitors in cancer treatment and Prevention, a recent development[J].Anticancer Drugs,2002,13(2):127-137
[5] Leng J,Han C,Demetris AJ,et al.Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt aetivation: evidence for Akt inhibition in celecoxib-induced apoptosis[J]. Herpatology,2003,38(3):756-768.
[6] Baguette J, Manfred JJ. Multiple roles of the tumor suppressor p53[J].Curr Opin Oncol,2002,14(1):86-91.
[7] Ambudkar SV,Kimchi SC, Sauna ZE, et al. P-glycoprotein: from genomies to mechanism[J]. Oncogene,2003,22(47):7468-7485.
[8] Lehne G. P-glycoprotein as a drug target in the treatment of multidrug resistance cancer[J]. Curr Drug Targets,2000,1(1):85-99.
[9] Patel VA, Dunn MJ, Sorokin A. Regulation of MDR-1(P-glycol-protein)by cyclooxygenase-2[J]. J Biol Chem, 2002, 277(41):38915-38920.
[10] Nardone G,Rocco A,Vaira D,et al. Expression of COX-2,mPGE-synthase1,MDR-1(P-gp), and Bcl-xL: a molecular pathway of Hpylori-related gastric carcinogenesis[J].J Pathol,2004,202(3):305-312.
[11] Sultana H, Kigawa J, Kanamori Y,et al. Chemo sensitivity and p53-Bax pathway-mediated apoptosis in patients with uterine cervical cancer[J].Ann Uncoil, 2003,14(2):214-219.
[12] Linn Sc,Honkoop AH,Hoekman K,et al. P53 and P-glycoprotein are often co- expressed associated with poor prognosis in breast cancer[J]. Br J Cancer,1996,74:63-68.

相似文献/References:

[1]白建平,卢建跃,孙新增,等.miR-21和miR-106a在乳腺癌组织中的表达及临床病理学意义[J].宁夏医科大学学报,2015,(05):553.[doi:10.16050/j.cnki.issn1674-6309.2015.05.020 ]
[2]尹明伟,辛淑文,隋御,等.下调REV3通过激活p53诱导结肠癌细胞THC-8307凋亡[J].宁夏医科大学学报,2015,(03):237.[doi:10.16050/j.cnki.issn1674-6309.2015.03.002 ]
 YIN Mingwei,XIN Shuwen,SUI Yu,et al.[J].Ningxia Medical University,2015,(05):237.[doi:10.16050/j.cnki.issn1674-6309.2015.03.002 ]
[3]张薇,何丽萍,李建宁,等.p53抑制剂PFT-α对犬博卡病毒感染致靶细胞病变的影响[J].宁夏医科大学学报,2015,(01):9.[doi:10.16050/j.cnki.issn1674-6309.2015.01.003]
 ZHANG Wei,HE Liping,LI Jianning,et al.[J].Ningxia Medical University,2015,(05):9.[doi:10.16050/j.cnki.issn1674-6309.2015.01.003]
[4]周晓明,张国昌,李 锋,等.P53、P21ras、Ki-67蛋白的表达及微血管密度 与甲状腺癌转移关系的研究[J].宁夏医科大学学报,2005,(06):443.[doi:10.3969/j.issn.1674-6309.2005.06.006]
 ZHOU Xiao-ming,ZHANG Guo-chang,LI Feng,et al.Clinical Significance of P53、P21ras、Ki-67 and MVD in Thyroid Carcinoma[J].Ningxia Medical University,2005,(05):443.[doi:10.3969/j.issn.1674-6309.2005.06.006]
[5]姜怡邓,张慧萍,张鸣号,等.妊娠高血压综合征患者血清中抗氧化物与胎盘Bax、Bcl-2关系的探讨[J].宁夏医科大学学报,2007,(03):240.
 JIANG Yi-deng,ZHANG Hui-ping,ZHANG Ming-hao,et al.Relationship Between Serum Antioxidants and the Expression of Bcl-2、Bax Apoptosis Protein of Placental Tissues with Pregnancy-induced Hypertension Syndrome[J].Ningxia Medical University,2007,(05):240.
[6]师卫华,尹 莉.乳腺癌患者P-gp表达与临床病理特征 及化疗后血液毒性的关系[J].宁夏医科大学学报,2011,(12):1157.
 SHI Wei-hua,YIN Li.The Relationship between the Expression of Multidrug Resistance P-Glycoprotein and Blood Toxicity after Chemotherapy in Patients with Breast Cancer[J].Ningxia Medical University,2011,(05):1157.
[7]墙 华,杨 丽,胡小平,等.线粒体DNA np16189和np16223多态性与 乳腺癌相关性研究[J].宁夏医科大学学报,2010,(08):849.
 QIANG Hua,YANG Li,HU Xiao-ping,et al.The Association between mtDNA np16189, np16223 Polymorphisms and Breast Cancer[J].Ningxia Medical University,2010,(05):849.
[8]丛芳圆,崔 洁,刘新兰,等.P-gp、BCRP、LRP在乳腺癌组织中的表达及其意义[J].宁夏医科大学学报,2010,(05):589.
 CONG Fang-yuan,CUI Jie,LIU Xin-lan,et al.Expression and Significance of P-gp, BCRP and LRP in Breast Carcinoma Tissues[J].Ningxia Medical University,2010,(05):589.
[9]王琰娟,米成嵘,王 文.乳腺癌前哨淋巴结的超声造影检查及 与乳腺癌组织ER、PR和HER-2表达的相关性[J].宁夏医科大学学报,2013,(05):528.
 WANG Yan-juan,MI Cheng-rong,WANG Wen.The Correlation of Contrast-enhanced Ultrasound in Sentine Lymph Node of Breast Cancer and Expression of ER, PR, HER-2 in Breast Cancer Tissues[J].Ningxia Medical University,2013,(05):528.
[10]丁永慧,徐永辉.MDM2和p53在宫颈鳞癌中的表达及与高危型HPV感染的关系[J].宁夏医科大学学报,2013,(01):26.
 DING Yong-hui,XU Yong-hui.Relationship between Expression of MDM2,p53 and HR-HPV in Patients with Cervical Squamous Cancer[J].Ningxia Medical University,2013,(05):26.

备注/Memo

备注/Memo:
收稿日期:2010-10-12 作者简介:马秀萍,女,在读硕士研究生,主治医师。 通信作者:张建中,男,教授,硕士研究生导师。
更新日期/Last Update: 2011-05-20